Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	pyruvate dehydrogenase (acetyl-transferring) kinase activity	PDK1 PDK4	2.33e-05	5	31	2	GO:0004740
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	ZHX3 NFKBIZ NR4A3 TCF7L2 TFAP2D NFAT5 UTY GLI2 SMAD4	2.67e-04	1459	31	9	GO:0000977
GeneOntologyMolecularFunction	chromatin binding	AUTS2 TCF7L2 NFAT5 UTY GLI2 SMAD4	8.39e-04	739	31	6	GO:0003682
GeneOntologyMolecularFunction	DNA-binding transcription activator activity, RNA polymerase II-specific	NR4A3 TCF7L2 NFAT5 GLI2 SMAD4	1.58e-03	560	31	5	GO:0001228
GeneOntologyMolecularFunction	DNA-binding transcription activator activity	NR4A3 TCF7L2 NFAT5 GLI2 SMAD4	1.66e-03	566	31	5	GO:0001216
GeneOntologyMolecularFunction	RNA polymerase II cis-regulatory region sequence-specific DNA binding	NFKBIZ NR4A3 TCF7L2 NFAT5 UTY GLI2 SMAD4	2.51e-03	1244	31	7	GO:0000978
GeneOntologyMolecularFunction	cis-regulatory region sequence-specific DNA binding	NFKBIZ NR4A3 TCF7L2 NFAT5 UTY GLI2 SMAD4	2.83e-03	1271	31	7	GO:0000987
GeneOntologyMolecularFunction	transcription coactivator binding	NR4A3 SMAD4	3.17e-03	54	31	2	GO:0001223
GeneOntologyBiologicalProcess	regulation of sulfur metabolic process	TCF7L2 PDK1 PDK4	1.86e-06	17	30	3	GO:0042762
GeneOntologyBiologicalProcess	regulation of acetyl-CoA biosynthetic process from pyruvate	PDK1 PDK4	1.22e-05	4	30	2	GO:0010510
GeneOntologyBiologicalProcess	regulation of acyl-CoA biosynthetic process	PDK1 PDK4	2.04e-05	5	30	2	GO:0050812
GeneOntologyBiologicalProcess	axon development	AUTS2 NR4A3 ARHGAP32 MAP3K13 TNFRSF21 GLI2 SMAD4	2.99e-05	642	30	7	GO:0061564
GeneOntologyBiologicalProcess	hindgut morphogenesis	TCF7L2 GLI2	7.32e-05	9	30	2	GO:0007442
GeneOntologyBiologicalProcess	hindgut development	TCF7L2 GLI2	9.14e-05	10	30	2	GO:0061525
GeneOntologyBiologicalProcess	positive regulation of transcription by RNA polymerase II	AUTS2 NFKBIZ NR4A3 TCF7L2 MAML2 TFAP2D NFAT5 GLI2 SMAD4	1.09e-04	1390	30	9	GO:0045944
GeneOntologyBiologicalProcess	neuron projection morphogenesis	AUTS2 NR4A3 ARHGAP32 MAP3K13 ATXN2 GLI2 SMAD4	1.22e-04	802	30	7	GO:0048812
GeneOntologyBiologicalProcess	plasma membrane bounded cell projection morphogenesis	AUTS2 NR4A3 ARHGAP32 MAP3K13 ATXN2 GLI2 SMAD4	1.39e-04	819	30	7	GO:0120039
GeneOntologyBiologicalProcess	axonogenesis	AUTS2 NR4A3 ARHGAP32 MAP3K13 GLI2 SMAD4	1.41e-04	566	30	6	GO:0007409
GeneOntologyBiologicalProcess	cell projection morphogenesis	AUTS2 NR4A3 ARHGAP32 MAP3K13 ATXN2 GLI2 SMAD4	1.46e-04	826	30	7	GO:0048858
GeneOntologyBiologicalProcess	acetyl-CoA biosynthetic process from pyruvate	PDK1 PDK4	1.58e-04	13	30	2	GO:0006086
GeneOntologyBiologicalProcess	cell morphogenesis	AUTS2 NR4A3 ARHGAP32 MAP3K13 ATXN2 POF1B GLI2 SMAD4	2.29e-04	1194	30	8	GO:0000902
GeneOntologyBiologicalProcess	developmental growth	AUTS2 ARHGAP32 TCF7L2 MAP3K13 ATXN2 GLI2 SMAD4	2.67e-04	911	30	7	GO:0048589
GeneOntologyBiologicalProcess	growth	AUTS2 NFKBIZ ARHGAP32 TCF7L2 MAP3K13 ATXN2 GLI2 SMAD4	2.89e-04	1235	30	8	GO:0040007
GeneOntologyBiologicalProcess	neuron projection development	AUTS2 NR4A3 ARHGAP32 MAP3K13 ATXN2 TNFRSF21 GLI2 SMAD4	3.78e-04	1285	30	8	GO:0031175
GeneOntologyBiologicalProcess	acetyl-CoA biosynthetic process	PDK1 PDK4	3.82e-04	20	30	2	GO:0006085
GeneOntologyBiologicalProcess	regulation of leukocyte cell-cell adhesion	NFKBIZ NR4A3 NFAT5 TNFRSF21 GLI2	4.26e-04	447	30	5	GO:1903037
GeneOntologyBiologicalProcess	leukocyte cell-cell adhesion	NFKBIZ NR4A3 NFAT5 TNFRSF21 GLI2	6.23e-04	486	30	5	GO:0007159
GeneOntologyBiologicalProcess	cell morphogenesis involved in neuron differentiation	AUTS2 NR4A3 ARHGAP32 MAP3K13 GLI2 SMAD4	6.28e-04	748	30	6	GO:0048667
GeneOntologyCellularComponent	nuclear body	CBLL1 ATXN2L NFKBIZ TCF7L2 MAML2 GLI2 NUFIP2	2.90e-04	903	31	7	GO:0016604
GeneOntologyCellularComponent	cytoplasmic stress granule	ATXN2L ATXN2 NUFIP2	3.84e-04	96	31	3	GO:0010494
GeneOntologyCellularComponent	nuclear speck	CBLL1 ATXN2L NFKBIZ MAML2 GLI2	3.97e-04	431	31	5	GO:0016607
GeneOntologyCellularComponent	cytoplasmic ribonucleoprotein granule	ATXN2L NFKBIZ ATXN2 NUFIP2	6.42e-04	269	31	4	GO:0036464
GeneOntologyCellularComponent	ribonucleoprotein granule	ATXN2L NFKBIZ ATXN2 NUFIP2	8.17e-04	287	31	4	GO:0035770
GeneOntologyCellularComponent	transcription regulator complex	NR4A3 TCF7L2 TFAP2D NFAT5 SMAD4	1.70e-03	596	31	5	GO:0005667
Domain	LsmAD	ATXN2L ATXN2	2.67e-06	2	31	2	PF06741
Domain	LsmAD_domain	ATXN2L ATXN2	2.67e-06	2	31	2	IPR009604
Domain	SM_dom_ATX	ATXN2L ATXN2	2.67e-06	2	31	2	IPR025852
Domain	SM-ATX	ATXN2L ATXN2	2.67e-06	2	31	2	PF14438
Domain	LsmAD	ATXN2L ATXN2	2.67e-06	2	31	2	SM01272
Domain	BCDHK_Adom3	PDK1 PDK4	2.66e-05	5	31	2	PF10436
Domain	His_kinase_dom	PDK1 PDK4	2.66e-05	5	31	2	IPR005467
Domain	HIS_KIN	PDK1 PDK4	2.66e-05	5	31	2	PS50109
Domain	-	PDK1 PDK4	2.66e-05	5	31	2	1.20.140.20
Domain	BCDHK/PDK_N	PDK1 PDK4	2.66e-05	5	31	2	IPR018955
Domain	PAM2	ATXN2L ATXN2	9.53e-05	9	31	2	PF07145
Domain	Ataxin-2_C	ATXN2L ATXN2	9.53e-05	9	31	2	IPR009818
Domain	HATPase_c	PDK1 PDK4	4.01e-04	18	31	2	SM00387
Domain	HATPase_c	PDK1 PDK4	4.48e-04	19	31	2	PF02518
Domain	-	PDK1 PDK4	4.97e-04	20	31	2	3.30.565.10
Domain	HATPase_C	PDK1 PDK4	5.49e-04	21	31	2	IPR003594
Domain	SH3_1	STAM2 ARHGAP32 GRAP2	2.49e-03	164	31	3	PF00018
Domain	SH3	STAM2 ARHGAP32 GRAP2	5.40e-03	216	31	3	PS50002
Domain	SH3	STAM2 ARHGAP32 GRAP2	5.40e-03	216	31	3	SM00326
Domain	SH3_domain	STAM2 ARHGAP32 GRAP2	5.68e-03	220	31	3	IPR001452
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	TCF7L2 MAML2 SMAD4	2.47e-04	76	23	3	MM15520
Pathway	REACTOME_REGULATION_OF_PYRUVATE_DEHYDROGENASE_PDH_COMPLEX	PDK1 PDK4	2.64e-04	15	23	2	MM14820
Pathway	REACTOME_REGULATION_OF_PYRUVATE_DEHYDROGENASE_PDH_COMPLEX	PDK1 PDK4	2.64e-04	15	23	2	M716
Pathway	REACTOME_FORMATION_OF_DEFINITIVE_ENDODERM	TCF7L2 SMAD4	3.41e-04	17	23	2	M48030
Pathway	REACTOME_LISTERIA_MONOCYTOGENES_ENTRY_INTO_HOST_CELLS	CBLL1 STAM2	4.75e-04	20	23	2	M27780
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	TCF7L2 MAML2 SMAD4	4.91e-04	96	23	3	M27784
Pathway	WP_DNA_DAMAGE_RESPONSE_ONLY_ATM_DEPENDENT	TCF7L2 PDK1 SMAD4	7.31e-04	110	23	3	M39492
Pathway	WP_HYPOTHESIZED_PATHWAYS_IN_PATHOGENESIS_OF_CARDIOVASCULAR_DISEASE	LTBP2 SMAD4	7.47e-04	25	23	2	M39713
Pathway	WP_TCA_CYCLE	PDK1 PDK4	1.15e-03	31	23	2	MM15856
Pathway	REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT	GLI2 SMAD4	1.15e-03	31	23	2	M27805
Pathway	REACTOME_GASTRULATION	TCF7L2 MAML2 SMAD4	1.16e-03	129	23	3	M46433
Pathway	REACTOME_GENERIC_TRANSCRIPTION_PATHWAY	AUTS2 NR4A3 TCF7L2 MAML2 TFAP2D SMAD4	1.16e-03	768	23	6	MM14851
Pathway	REACTOME_REGULATION_OF_PYRUVATE_METABOLISM	PDK1 PDK4	1.30e-03	33	23	2	M48274
Pathway	REACTOME_REGULATION_OF_PYRUVATE_METABOLISM	PDK1 PDK4	1.30e-03	33	23	2	MM17246
Pubmed	Expression of oxidored nitro domain-containing protein 1(NOR1) impairs nasopharyngeal carcinoma cells adaptation to hypoxia and inhibits PDK1 expression.	NR4A3 PDK1	8.20e-07	2	32	2	24788728
Pubmed	RP11-495P10.1 promotes HCC cell proliferation by regulating reprogramming of glucose metabolism and acetylation of the NR4A3 promoter via the PDK1/PDH axis.	NR4A3 PDK1	8.20e-07	2	32	2	37905340
Pubmed	Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.	ATXN2L ATXN2	8.20e-07	2	32	2	8896555
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	ARHGAP32 PRR14 TCF7L2 MAML2 ATXN2 GLI2	2.38e-06	430	32	6	35044719
Pubmed	Ataxin-2-like is a regulator of stress granules and processing bodies.	ATXN2L ATXN2	2.46e-06	3	32	2	23209657
Pubmed	The embryonic patterning gene Dbx1 governs the survival of the auditory midbrain via Tcf7l2-Ap2δ transcriptional cascade.	TCF7L2 TFAP2D	2.46e-06	3	32	2	37081114
Pubmed	Pyruvate dehydrogenase activation and kinase expression in human skeletal muscle during fasting.	PDK1 PDK4	2.46e-06	3	32	2	14966024
Pubmed	Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules.	ATXN2L ATXN2	4.92e-06	4	32	2	17392519
Pubmed	Tissue-specific kinase expression and activity regulate flux through the pyruvate dehydrogenase complex.	PDK1 PDK4	4.92e-06	4	32	2	30482839
Pubmed	Formation of functional heterodimers by isozymes 1 and 2 of pyruvate dehydrogenase kinase.	PDK1 PDK4	4.92e-06	4	32	2	12573248
Pubmed	Differing roles of pyruvate dehydrogenase kinases during mouse oocyte maturation.	PDK1 PDK4	4.92e-06	4	32	2	25991547
Pubmed	Diversity of the pyruvate dehydrogenase kinase gene family in humans.	PDK1 PDK4	4.92e-06	4	32	2	7499431
Pubmed	Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.	ATXN2L STAM2 GRAP2 NUFIP2	6.76e-06	133	32	4	15144186
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	ZHX3 NFKBIZ PRR14 TCF7L2 NFAT5 UTY SMAD4	7.22e-06	808	32	7	20412781
Pubmed	Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex.	PDK1 PDK4	8.19e-06	5	32	2	11978179
Pubmed	Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites.	PDK1 PDK4	8.19e-06	5	32	2	11485553
Pubmed	Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase.	PDK1 PDK4	8.19e-06	5	32	2	11486000
Pubmed	Efficient T-cell receptor signaling requires a high-affinity interaction between the Gads C-SH3 domain and the SLP-76 RxxK motif.	STAM2 GRAP2	8.19e-06	5	32	2	17235283
Pubmed	The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery.	CBLL1 AUTS2 ATXN2L NR4A3 TCF7L2 ATXN2 GLI2 NUFIP2	1.00e-05	1203	32	8	29180619
Pubmed	BCKDK regulates the TCA cycle through PDC in the absence of PDK family during embryonic development.	PDK1 PDK4	1.23e-05	6	32	2	33773101
Pubmed	A census of human transcription factors: function, expression and evolution.	ZHX3 NR4A3 TCF7L2 TFAP2D NFAT5 GLI2 SMAD4	1.54e-05	908	32	7	19274049
Pubmed	AMSH interacts with ESCRT-0 to regulate the stability and trafficking of CXCR4.	STAM2 GRAP2	1.72e-05	7	32	2	20159979
Pubmed	The RNA-binding ubiquitin ligase MKRN1 functions in ribosome-associated quality control of poly(A) translation.	ATXN2L ATXN2 NUFIP2	1.80e-05	55	32	3	31640799
Pubmed	Requirement of Smad4 from Ocular Surface Ectoderm for Retinal Development.	GLI2 SMAD4	2.29e-05	8	32	2	27494603
Pubmed	Wnt signaling inhibitors regulate the transcriptional response to morphogenetic Shh-Gli signaling in the neural tube.	TCF7L2 GLI2	2.94e-05	9	32	2	16950124
Pubmed	Expression of signaling components in embryonic eyelid epithelium.	TCF7L2 GLI2	3.67e-05	10	32	2	24498290
Pubmed	Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs.	PDK1 PDK4	5.38e-05	12	32	2	12676647
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	AUTS2 PRR14 TCF7L2 ATXN2 SEC24A	5.76e-05	457	32	5	32344865
Pubmed	Comprehensive Protein Interactome Analysis of a Key RNA Helicase: Detection of Novel Stress Granule Proteins.	ATXN2 NUFIP2	8.55e-05	15	32	2	26184334
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	ARHGAP32 ATXN2 SEC24A NUFIP2	9.73e-05	263	32	4	34702444
Pubmed	The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression.	ATXN2L ATXN2 NUFIP2	9.84e-05	97	32	3	37151849
Pubmed	UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.	ATXN2L STAM2 ATXN2 NUFIP2	1.03e-04	267	32	4	33417871
Pubmed	Stage-specific regulation of oligodendrocyte development by Wnt/β-catenin signaling.	TCF7L2 GLI2	1.11e-04	17	32	2	24948802
Pubmed	Wnt-Dependent Inactivation of the Groucho/TLE Co-repressor by the HECT E3 Ubiquitin Ligase Hyd/UBR5.	ATXN2L TCF7L2	1.24e-04	18	32	2	28689657
Pubmed	Unique mechanisms of growth regulation and tumor suppression upon Apc inactivation in the pancreas.	TCF7L2 SMAD4	1.39e-04	19	32	2	17596282
Pubmed	Secreted retrovirus-like GAG-domain-containing protein PEG10 is regulated by UBE3A and is involved in Angelman syndrome pathophysiology.	ATXN2L ATXN2	1.39e-04	19	32	2	34467244
Pubmed	Fuz regulates craniofacial development through tissue specific responses to signaling factors.	TCF7L2 GLI2	1.54e-04	20	32	2	21935430
Pubmed	Pinin modulates expression of an intestinal homeobox gene, Cdx2, and plays an essential role for small intestinal morphogenesis.	TCF7L2 GLI2	1.54e-04	20	32	2	20637749
Pubmed	Tcf/Lef repressors differentially regulate Shh-Gli target gene activation thresholds to generate progenitor patterning in the developing CNS.	TCF7L2 GLI2	1.87e-04	22	32	2	21775418
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	CBLL1 ATXN2L ZHX3 FAM168A ATXN2 NUFIP2	2.06e-04	954	32	6	36373674
Pubmed	Vti1b promotes TRPV1 sensitization during inflammatory pain.	ATXN2L ATXN2 NUFIP2	2.18e-04	127	32	3	30335684
Pubmed	A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.	ATXN2L ZHX3 STAM2 ARHGAP32 ATXN2	2.19e-04	608	32	5	16713569
Pubmed	Human transcription factor protein interaction networks.	AUTS2 ZHX3 ARHGAP32 TCF7L2 ATXN2 GLI2 SEC24A	2.66e-04	1429	32	7	35140242
Pubmed	Dbx1 is a dorsal midbrain-specific determinant of GABAergic neuron fate and regulates differentiation of the dorsal midbrain into the inferior and superior colliculi.	TCF7L2 TFAP2D	3.05e-04	28	32	2	38344749
Pubmed	pRb-mediated control of epithelial cell proliferation and Indian hedgehog expression in mouse intestinal development.	TCF7L2 GLI2	3.51e-04	30	32	2	17257418
Pubmed	Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways.	ATXN2L ATXN2 SMAD4	3.70e-04	152	32	3	16009940
Pubmed	Proline-rich sequence recognition: II. Proteomics analysis of Tsg101 ubiquitin-E2-like variant (UEV) interactions.	ATXN2 NUFIP2	4.00e-04	32	32	2	19542561
Pubmed	Genetic variations in humans associated with differences in the course of hepatitis C.	LTBP2 GRAP2	4.00e-04	32	32	2	15063762
Pubmed	Secreted protein acidic and rich in cysteine (SPARC) gene polymorphism association with hepatocellular carcinoma in Italian patients.	LTBP2 GRAP2	4.25e-04	33	32	2	19817957
Pubmed	Polycomb-Mediated Repression and Sonic Hedgehog Signaling Interact to Regulate Merkel Cell Specification during Skin Development.	TCF7L2 GLI2	4.25e-04	33	32	2	27414999
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	ATXN2L STAM2 ARHGAP32 SEC24A NUFIP2	4.40e-04	708	32	5	39231216
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	ZHX3 NR4A3 TCF7L2 NFAT5 GLI2	4.43e-04	709	32	5	22988430
Pubmed	Spatiotemporal-resolved protein networks profiling with photoactivation dependent proximity labeling.	ATXN2L ZHX3 ATXN2 NUFIP2	4.76e-04	399	32	4	35987950
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	ZHX3 FAM168A NFAT5 NUFIP2	5.13e-04	407	32	4	12693553
Pubmed	ZBTB10 binds the telomeric variant repeat TTGGGG and interacts with TRF2.	ATXN2L ATXN2	5.65e-04	38	32	2	30629181
Pubmed	Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury.	PDK1 PDK4	5.65e-04	38	32	2	20185832
Pubmed	CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity.	ATXN2L ATXN2 POF1B NUFIP2	5.67e-04	418	32	4	35338135
Pubmed	Pooled-matrix protein interaction screens using Barcode Fusion Genetics.	TCF7L2 MAML2 SMAD4 GRAP2	5.72e-04	419	32	4	27107012
Pubmed	Regulation of epidermal differentiation through KDF1-mediated deubiquitination of IKKα.	ATXN2 SMAD4 NUFIP2	6.25e-04	182	32	3	32239614
Pubmed	Transcriptional Networks Controlled by NKX2-1 in the Development of Forebrain GABAergic Neurons.	TCF7L2 GLI2	6.26e-04	40	32	2	27657450
Pubmed	A non-proteolytic role for ubiquitin in deadenylation of MHC-I mRNA by the RNA-binding E3-ligase MEX-3C.	ATXN2L NUFIP2	7.57e-04	44	32	2	26471122
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	ATXN2L ATXN2 PDK1 NUFIP2	8.23e-04	462	32	4	31138677
Pubmed	LONP1-mediated mitochondrial quality control safeguards metabolic shifts in heart development.	PDK1 PDK4	8.28e-04	46	32	2	35237793
Pubmed	Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.	CBLL1 NFKBIZ STAM2 POF1B	8.70e-04	469	32	4	27634302
Pubmed	Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.	ATXN2L NFAT5 ATXN2 NUFIP2	9.12e-04	475	32	4	31040226
Interaction	PTPN23 interactions	ATXN2L STAM2 ARHGAP32 ATXN2 GRAP2	4.53e-06	162	31	5	int:PTPN23
Interaction	DCP1B interactions	ATXN2L ATXN2 SMAD4 NUFIP2	1.89e-05	104	31	4	int:DCP1B
Interaction	KRTAP7-1 interactions	TCF7L2 TFAP2D FAM168A	2.68e-05	38	31	3	int:KRTAP7-1
Interaction	KPRP interactions	NR4A3 TFAP2D MYCBPAP GRAP2 NUFIP2	6.75e-05	284	31	5	int:KPRP
Cytoband	9q34.11	IER5L PIP5KL1	6.34e-04	53	32	2	9q34.11
Coexpression	MOOTHA_PYR	PDK1 PDK4	4.02e-05	8	32	2	M5871
Coexpression	TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_EPITHELIAL_CELL_AGEING	ATXN2L NFKBIZ TCF7L2 MAML2 PDK1 SMAD4	5.66e-05	568	32	6	MM3824
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP	AUTS2 NFKBIZ NR4A3 LTBP2	7.25e-05	184	32	4	M8544
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP	AUTS2 NFKBIZ NR4A3 LTBP2	7.88e-05	188	32	4	MM983
Coexpression	HOLLERN_SOLID_NODULAR_BREAST_TUMOR_UP	MAP3K13 POF1B	7.89e-05	11	32	2	M742
Coexpression	GSE11057_EFF_MEM_VS_CENT_MEM_CD4_TCELL_DN	MAML2 NFAT5 MYCBPAP PDK1	8.04e-05	189	32	4	M3112
Coexpression	GSE17974_0H_VS_72H_IN_VITRO_ACT_CD4_TCELL_UP	AUTS2 NFKBIZ TCF7L2 TNFRSF21	8.72e-05	193	32	4	M4177
Coexpression	GSE32986_GMCSF_VS_GMCSF_AND_CURDLAN_LOWDOSE_STIM_DC_DN	NFKBIZ ARHGAP32 MAML2 PDK1	9.44e-05	197	32	4	M8611
Coexpression	GSE2706_UNSTIM_VS_8H_R848_DC_DN	NFKBIZ NR4A3 TCF7L2 MAML2	9.44e-05	197	32	4	M4694
Coexpression	GSE3982_BCELL_VS_CENT_MEMORY_CD4_TCELL_DN	AUTS2 NR4A3 FAM168A GRAP2	9.62e-05	198	32	4	M5545
Coexpression	GSE32986_UNSTIM_VS_GMCSF_STIM_DC_UP	NFKBIZ ARHGAP32 MAML2 PDK1	9.81e-05	199	32	4	M8609
Coexpression	GSE14000_UNSTIM_VS_4H_LPS_DC_DN	NFKBIZ NR4A3 MAP3K13 NFAT5	9.81e-05	199	32	4	M3347
Coexpression	GSE40666_UNTREATED_VS_IFNA_STIM_STAT4_KO_EFFECTOR_CD8_TCELL_90MIN_DN	ZHX3 ARHGAP32 MAML2 GRAP2	9.81e-05	199	32	4	M9236
Coexpression	GSE25123_WT_VS_PPARG_KO_MACROPHAGE_UP	NFKBIZ TCF7L2 MAML2 SND1-IT1	9.81e-05	199	32	4	M7951
Coexpression	GSE40277_GATA1_AND_SATB1_TRANSDUCED_VS_CTRL_CD4_TCELL_DN	NR4A3 TCF7L2 CCNJ ATXN2	9.81e-05	199	32	4	M9178
Coexpression	GSE31082_DN_VS_CD8_SP_THYMOCYTE_DN	NFKBIZ NR4A3 NFAT5 GRAP2	1.00e-04	200	32	4	M5063
Coexpression	BROWNE_HCMV_INFECTION_20HR_UP	ATXN2L NR4A3 ARHGAP32 MAP3K13	1.86e-04	235	32	4	M6122
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder neck-urethr epithel_emap-30875_top-relative-expression-ranked_1000	AUTS2 NFKBIZ NR4A3 TCF7L2 PDK1 UTY POF1B NUFIP2	1.43e-05	800	31	8	gudmap_developingLowerUrinaryTract_e13.5_bladder neck-urethr epithel_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-6668_top-relative-expression-ranked_500	ZHX3 NR4A3 NFAT5 UTY PDK4 POF1B	2.87e-05	422	31	6	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-6668_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_P1_bladder_J_emap-30374_k-means-cluster#1_top-relative-expression-ranked_1000	ZHX3 LTBP2 NFAT5 PDK4	6.32e-05	149	31	4	gudmap_developingLowerUrinaryTract_P1_bladder_J_1000_k1
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder neck-urethr epithel_emap-30875_k-means-cluster#2_top-relative-expression-ranked_1000	AUTS2 NFKBIZ PDK1 UTY	6.49e-05	150	31	4	gudmap_developingLowerUrinaryTract_e13.5_bladder neck-urethr epithel_1000_k2
CoexpressionAtlas	DevelopingLowerUrinaryTract_P1_bladder_J_emap-30374_top-relative-expression-ranked_1000	ZHX3 NR4A3 LTBP2 NFAT5 PDK4 POF1B SEC24A	1.00e-04	772	31	7	gudmap_developingLowerUrinaryTract_P1_bladder_1000_J
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_top-relative-expression-ranked_1000	CBLL1 AUTS2 NFKBIZ PDK1 UTY POF1B SEC24A	1.64e-04	836	31	7	gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder neck-urethr epithel_emap-30875_k-means-cluster#2_top-relative-expression-ranked_500	NFKBIZ NR4A3 NUFIP2	1.70e-04	74	31	3	gudmap_developingLowerUrinaryTract_e13.5_bladder neck-urethr epithel_500_k2
ToppCell	Control-CD4+_T_activated\|World / Disease group and Cell class	MAP3K13 SND1-IT1 PDK1 PDK4	6.98e-06	173	32	4	12f8e4276b290bb388a56de4c8d8dd60415b2f63
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature4_(1)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	NFKBIZ NR4A3 NFAT5 NUFIP2	1.05e-05	192	32	4	6bba80887d6f64cf913a5c22f62baaddda417ce0
ToppCell	10x3'2.3-week_17-19\|World / cell types per 3 fetal stages;per 3',per 5'	NFKBIZ IER5L UTY NUFIP2	1.16e-05	197	32	4	f5cfad0b42d0f817e22cc78b9bfb2b4b7e4330ed
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	AUTS2 ARHGAP32 MAML2 UTY	1.21e-05	199	32	4	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2-Th.Nr4a2_(Neuron.Gad1Gad2-Th.Nr4a2)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	LTBP2 PDK4 POF1B	4.19e-05	94	32	3	9664f74bc0168c92fb8a68cad628323c476f6103
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2-Th.Nr4a2_(Neuron.Gad1Gad2-Th.Nr4a2)--\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	LTBP2 PDK4 POF1B	4.19e-05	94	32	3	c73e99890431750b74f984de5c82e33533ab708b
ToppCell	Posterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2-Th.Nr4a2_(Neuron.Gad1Gad2-Th.Nr4a2)-\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	LTBP2 PDK4 POF1B	4.19e-05	94	32	3	1bda61101f45f5c4a68453087b880fdc6d9acfca
ToppCell	ILEUM-non-inflamed-(3)_MNP-(3)_moDC\|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	NR4A3 SND1-IT1 ATXN2	1.23e-04	135	32	3	b7a792a7c0c22d8b703509f134115f0e394d7de0
ToppCell	primary_visual_cortex-Non-neuronal-astrocyte\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TCF7L2 PDK4 GLI2	1.78e-04	153	32	3	95b28c5bd10ffb74c0993ebd565038b9818e4bd2
ToppCell	primary_visual_cortex-Non-neuronal-astrocyte-Astro\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TCF7L2 PDK4 GLI2	1.78e-04	153	32	3	b09f8def40a1ea56722f3398f61a036667b61cd9
ToppCell	primary_visual_cortex-Non-neuronal-astrocyte-Astro-Astro_Aqp4\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TCF7L2 PDK4 GLI2	1.78e-04	153	32	3	3ab9d55b3db51715c1d61eca142384195ce4b54f
ToppCell	343B-Myeloid-Mast_cell-\|343B / Donor, Lineage, Cell class and subclass (all cells)	NFKBIZ NR4A3 GRAP2	2.03e-04	160	32	3	a2f09b5955602819c8978f4372130c8ef915cd07
ToppCell	343B-Myeloid-Mast_cell\|343B / Donor, Lineage, Cell class and subclass (all cells)	NFKBIZ NR4A3 GRAP2	2.03e-04	160	32	3	133ecae0a894d9a0d49d58859623359096b6f030
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-E\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NR4A3 PDK4 NUFIP2	2.14e-04	163	32	3	a6e272e043859858084b8d4d96fa4ff9e6eca454
ToppCell	droplet-Bladder-BLADDER-1m-Epithelial-basal_bladder_epithelial_cell_(Krt5+)\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGAP32 PDK1 PDK4	2.22e-04	165	32	3	936581de8fcd097401707438b9bbe89dd4e3e247
ToppCell	5'-Adult-Appendix-Hematopoietic-Plasma_cells-IgG_plasma_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SND1-IT1 PDK1 PIP5KL1	2.22e-04	165	32	3	79c6ad394266ff092029375883660028e944a3c8
ToppCell	Children_(3_yrs)-Mesenchymal-chondrocyte-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NR4A3 LTBP2 CCNJ	2.30e-04	167	32	3	f4943fb5001475ddab82a0273bcbb3fa68fdd7bd
ToppCell	TCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma-Intrahepatic-2\|TCGA-Bile_Duct / Sample_Type by Project: Shred V9	CBLL1 LTBP2 MAML2	2.34e-04	168	32	3	c70bf73bb800e4722cedc35bbc17ea3113d1012d
ToppCell	COVID-19-Myeloid-MoAM5,_CCL3L1\|Myeloid / Condition, Lineage and Cell class	NFKBIZ NR4A3 NFAT5	2.34e-04	168	32	3	ea465152ea31391b63c02425beafa9a4f51f6703
ToppCell	3'_v3-bone_marrow-Mast-Mast_cell_lympho\|bone_marrow / Manually curated celltypes from each tissue	NR4A3 SND1-IT1 GRAP2	2.43e-04	170	32	3	4dedf482cd4521b3f87d2b5ae80f7a3ea8686a15
ToppCell	NS-critical-d_0-4-Epithelial-FOXN4+\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ZHX3 TNFRSF21 PIP5KL1	2.51e-04	172	32	3	a00bb44d33658cb3a98accd6b60f3ce964c425b4
ToppCell	facs-Brain_Myeloid-Cerebellum-3m-Myeloid-nan\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NFKBIZ MAML2 NUFIP2	2.55e-04	173	32	3	869da6a65d1b9b7529c666ec44e3c8ddec2ea408
ToppCell	facs-Brain_Myeloid-Cerebellum-3m-Myeloid\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NFKBIZ MAML2 NUFIP2	2.55e-04	173	32	3	0672bd8a4a9d18af343d01f09253fb3388896c10
ToppCell	COVID-19-Myeloid-MoAM5,_CCL3L1\|COVID-19 / Condition, Lineage and Cell class	NFKBIZ NR4A3 NFAT5	2.55e-04	173	32	3	502f888b7684ed39f5c577eedcacf673ae81d39e
ToppCell	facs-Brain_Myeloid-Cerebellum-3m\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NFKBIZ MAML2 NUFIP2	2.55e-04	173	32	3	870e091ec30be01a900e1cb8b9ef1880e3b7b50d
ToppCell	3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ZHX3 LTBP2 MAML2	2.64e-04	175	32	3	1799a7be623dc3bf53ba580a7c47d2619969d708
ToppCell	facs-Brain_Myeloid-Cerebellum-3m-Myeloid-microglial_cell\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NFKBIZ MAML2 NUFIP2	2.64e-04	175	32	3	1ea6cf9da26601646f57fa14d558a5e9e1f0b345
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like-MAIT\|lymph-node_spleen / Manually curated celltypes from each tissue	AUTS2 NFKBIZ IER5L	2.69e-04	176	32	3	25c197d3b39deffa4801a1d12cdb54320cbae509
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	AUTS2 NR4A3 IER5L	2.73e-04	177	32	3	84930899eb2978598bc8a351cbcd9e714e46799d
ToppCell	COPD-Myeloid-pDC\|COPD / Disease state, Lineage and Cell class	AUTS2 NR4A3 TNFRSF21	2.73e-04	177	32	3	415aa023195a7f961c09529f65cdcc7bb90eaf5d
ToppCell	IPF-Myeloid-pDC\|IPF / Disease state, Lineage and Cell class	AUTS2 NR4A3 TNFRSF21	2.78e-04	178	32	3	8d9e28492e1f157bac3308aa947fd864ca16d277
ToppCell	droplet-Liver-LIVER_NPC-30m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZHX3 ARHGAP32 UTY	2.82e-04	179	32	3	025d414ec88d5680d99c8173e70ee3bb0b694f74
ToppCell	3'-Broncho-tracheal-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFKBIZ NR4A3 GRAP2	2.82e-04	179	32	3	40441de2d679733ecbf2145fabc3ed65a53310eb
ToppCell	renal_papilla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	AUTS2 NFAT5 PDK4	2.87e-04	180	32	3	49829e833fe6d2431cfd2e8f378c2aaa3b2b46a4
ToppCell	COPD-Myeloid-DC_Mature\|World / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	2.91e-04	181	32	3	675603a401d92cf9fdcd44e211ec899fa86a0d49
ToppCell	droplet-Liver-nan-3m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARHGAP32 MAML2 PDK4	2.91e-04	181	32	3	fcc94f04dae98b817ec06b282d2e887804d37ae5
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NFKBIZ IER5L NUFIP2	3.01e-04	183	32	3	62f76907e501bba6e1010b5c447faed5f0ef93a7
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I-E\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NR4A3 IER5L PDK4	3.01e-04	183	32	3	614a1c08cf6d01a4f1ed2fb816cd1a6e0c3207ce
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	MAML2 PDK1 GRAP2	3.01e-04	183	32	3	f2ef110bf29b1a8276ef216238363e542db262c1
ToppCell	ILEUM-inflamed-(1)_T_cell-(1)_CD8_Trm\|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	AUTS2 NFKBIZ NR4A3	3.06e-04	184	32	3	cef3ee2a4a0af961aa3b4c92150d423e841ae8c1
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	AUTS2 NR4A3 GRAP2	3.06e-04	184	32	3	4f4aeef3b821a003e857fe4a195124d44b2d7479
ToppCell	normal-na-Lymphocytic_T-T8_naive-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	MAML2 PDK1 UTY	3.06e-04	184	32	3	4a81190b36d197736663e6177d3b76c1cb6282d6
ToppCell	(4)_Mast_cells\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	NFKBIZ NR4A3 GRAP2	3.11e-04	185	32	3	3dd5d2237ab50b13a41c12f85e1b79cd72ea567b
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c5-WDR74\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	TCF7L2 TNFRSF21 PDK4	3.11e-04	185	32	3	68edb1bb03ed221d49e583123ca4de14252d7bc5
ToppCell	(4)_Mast_cells\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	NFKBIZ NR4A3 GRAP2	3.11e-04	185	32	3	c91e1081e630a61c18f6af6d198bfcf296746852
ToppCell	IPF-Myeloid-DC_Mature\|World / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.16e-04	186	32	3	d0d3953d9b199e0e792990b8551efb993393fe7e
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATXN2L NR4A3 IER5L	3.16e-04	186	32	3	bd1185592aedebccd1007dbf2dd2f549fcdf9f42
ToppCell	IPF-Myeloid-cDC1\|World / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.16e-04	186	32	3	962c2dada19185628ead77c32fcb07fa95114247
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-Classical_Dendritic_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AUTS2 NR4A3 GRAP2	3.16e-04	186	32	3	305f1726b8b5add32f1c29c74991ff34f42e0da7
ToppCell	343B-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	LTBP2 PDK4 GLI2	3.16e-04	186	32	3	9673367cb53bafb873a01ef6bda11d9f392ce648
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MAML2 PDK4 GLI2	3.21e-04	187	32	3	5c73010fe4c85fb5cc1273f5504821229ca0cc4b
ToppCell	Control-Myeloid-DC_Mature\|Control / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.21e-04	187	32	3	049780ca2a3e6adcd89dc2cf3095b5ad068b244a
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-F\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	NFKBIZ NR4A3 PDK4	3.21e-04	187	32	3	98026c1aaf8de280470ad75536121357934fc78d
ToppCell	LA-01._Fibroblast_I\|World / Chamber and Cluster_Paper	LTBP2 MAML2 GLI2	3.21e-04	187	32	3	4ea486991f66c29728d127171a07b81404ec0b78
ToppCell	IPF-Myeloid-DC_Mature\|IPF / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.21e-04	187	32	3	63e0304a0183b69aebb0d1a4640a506a0d6fb6e9
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MAML2 PDK4 GLI2	3.21e-04	187	32	3	5d3d68519c8e19f10c29f9d81712125be78ca15a
ToppCell	COPD-Myeloid-DC_Mature\|COPD / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.26e-04	188	32	3	de93ccb53edb8599da9e312db0e3af604c21f673
ToppCell	IPF-Myeloid-cDC1\|Myeloid / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.26e-04	188	32	3	47bb6caf84f70a1cda7d09803afdfd5182772e66
ToppCell	facs-Mammary_Gland-Mammary_Gland-18m\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NR4A3 TCF7L2 PDK4	3.26e-04	188	32	3	5e13725136114e42d3b59647cf25e0f3c53abb54
ToppCell	facs-Brain_Non-Myeloid-Striatum_-18m-Epithelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LTBP2 POF1B GLI2	3.31e-04	189	32	3	6f0fc5271a7d3682f145e734abc3be6473dda2e2
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	MAML2 PDK1 GRAP2	3.31e-04	189	32	3	e9df7ecd36bee1fedce23bb188c68a94fa60462c
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	MAML2 NFAT5 UTY	3.31e-04	189	32	3	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	renal_cortex_nuclei-Adult_normal_reference\|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	ZHX3 UTY PDK4	3.31e-04	189	32	3	a48df46274d51e84ffb40264646de7346104efb9
ToppCell	facs-Mammary_Gland-Mammary_Gland-21m-Epithelial\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATXN2L NR4A3 IER5L	3.31e-04	189	32	3	965e0e388251e7318f8b463816dc96ccb4658677
ToppCell	IPF-Myeloid-DC_Mature\|Myeloid / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.31e-04	189	32	3	49e67d298d045f29136919b7d9971b6502b0efaa
ToppCell	facs-Brain_Non-Myeloid-Striatum_-18m-Epithelial-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LTBP2 POF1B GLI2	3.31e-04	189	32	3	3b9ce8964b16cb2200d30cbb0bfc711dcad2380e
ToppCell	facs-Brain_Non-Myeloid-Striatum_-18m-Epithelial-neuroepithelial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LTBP2 POF1B GLI2	3.31e-04	189	32	3	38acb307907fde68b992057714448c1561d69ee3
ToppCell	renal_medulla_nuclei-Adult_normal_reference\|renal_medulla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	AUTS2 ZHX3 PDK4	3.36e-04	190	32	3	f1363f7806cfc4f14fbc1b0e8dac2de813a88eee
ToppCell	facs-Mammary_Gland-Mammary_Gland-18m-Epithelial\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NR4A3 TCF7L2 PDK4	3.36e-04	190	32	3	92456f6f7eced6e4c4371f495254a65d061c8d0b
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c06-TNF\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	AUTS2 NR4A3 IER5L	3.41e-04	191	32	3	04faa7d2237e45418611153294eb6f7bb690cbde
ToppCell	Influenza_Severe-Non-classical_Monocyte\|Influenza_Severe / Disease group and Cell class	TCF7L2 IER5L PDK4	3.41e-04	191	32	3	197edf6feb1cfc71d88e532d74f77305a42a3486
ToppCell	LV-02._Fibroblast_II\|World / Chamber and Cluster_Paper	NFKBIZ LTBP2 MAML2	3.41e-04	191	32	3	d36565257ccba8c1bbed2c1c01be66a9cbb5f834
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	NFKBIZ MAML2 PDK1	3.41e-04	191	32	3	696921a4f160b6b55698652488ed781e855e5e51
ToppCell	390C-Myeloid-Mast_cell-\|390C / Donor, Lineage, Cell class and subclass (all cells)	NFKBIZ NR4A3 GRAP2	3.41e-04	191	32	3	88bcd0b85b2112cef15c9e44d1429f9fba4a3400
ToppCell	390C-Myeloid-Mast_cell\|390C / Donor, Lineage, Cell class and subclass (all cells)	NFKBIZ NR4A3 GRAP2	3.41e-04	191	32	3	c1517ea7b10a7f732725b4c0224fbfecae80d18b
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AUTS2 NR4A3 GLI2	3.46e-04	192	32	3	4022f208eb5db760abd0aac782a25e8ab63efc64
ToppCell	3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFKBIZ NR4A3 GRAP2	3.46e-04	192	32	3	60a02e0ccdc8c7af9bc875b248467304fe0d24a4
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2-D122\|Adult / Lineage, Cell type, age group and donor	AUTS2 MAP3K13 UTY	3.46e-04	192	32	3	06013a07e3a873b1d1c0451643c528593ac32a9c
ToppCell	COPD-Myeloid-DC_Mature\|Myeloid / Disease state, Lineage and Cell class	AUTS2 NR4A3 MAP3K13	3.46e-04	192	32	3	baebd462f464e7d0e462d07a74bb5d685a9fc3b6
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AUTS2 NR4A3 GLI2	3.46e-04	192	32	3	9333aba0d04203ccccad78d82bf6359922f810a7
ToppCell	3'-Parenchyma_lung-Immune_Myeloid_mast\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFKBIZ NR4A3 GRAP2	3.46e-04	192	32	3	5532ea1bc012eb9303197b87e90bc39619b5ee2a
ToppCell	3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFKBIZ NR4A3 GRAP2	3.46e-04	192	32	3	b223fca73e16668f69a78cf4457e349d01792540
ToppCell	10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	NFKBIZ MAML2 UTY	3.46e-04	192	32	3	47646d7e4990be85072987f92bf18d52f8da752e
ToppCell	3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFKBIZ NR4A3 GRAP2	3.46e-04	192	32	3	b5615a780b0ba24a8e554fac9238d3f0bcba52bc
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MAML2 PDK1 GRAP2	3.52e-04	193	32	3	6436d3bfce02d137b76e5c4c8b2fe27974c57c99
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	MAML2 PDK1 GRAP2	3.52e-04	193	32	3	95f5611dd9583f339b7c9f52bb478af204fb89ad
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFKBIZ TNFRSF21 PIP5KL1	3.52e-04	193	32	3	7cd9671e0ac64f7f3607f564485c63abbb7e7a63
ToppCell	distal-Hematologic-Basophil/Mast_2-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NFKBIZ NR4A3 GRAP2	3.52e-04	193	32	3	f22d0a2ea6bbdd625909ccb6a89aca89ab670306
ToppCell	LA\|World / Chamber and Cluster_Paper	LTBP2 MAML2 GLI2	3.52e-04	193	32	3	d4bf89437216baf489ea0239136dcedf3b6714af
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MAML2 FAM168A NFAT5	3.52e-04	193	32	3	779276e775cb2492e8dd36436295a536084a6415
ToppCell	LV-01._Fibroblast_I\|LV / Chamber and Cluster_Paper	NFKBIZ LTBP2 MAML2	3.52e-04	193	32	3	dc17f3b9758936d428cf17f77a1ce6d4c479b165
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MAML2 PDK1 GRAP2	3.52e-04	193	32	3	3cde93bbfc1ae6fb586ae6b7aaa6ed8b5eee28a4
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MAML2 PDK1 GRAP2	3.52e-04	193	32	3	d755dc6de4fbd4d8f5d8a88aac497e7b9e8b89de
ToppCell	normal-na-Myeloid-non-classical_monocyte-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	NFKBIZ TCF7L2 UTY	3.52e-04	193	32	3	053adc7ed9f997b503e12239a684bb9f5896e10c
ToppCell	10x5'-GI_small-bowel\|World / Manually curated celltypes from each tissue	NFKBIZ IER5L GRAP2	3.52e-04	193	32	3	cd89dfe53a114078f06343049685883c8e26508f
ToppCell	3'-GW_trimst-2-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	NFKBIZ TNFRSF21 PIP5KL1	3.52e-04	193	32	3	96c85b250d04b5f400512097d925061c6dc2906b
ToppCell	Control-CD8+_T_naive\|Control / Disease condition and Cell class	MAML2 PDK1 GRAP2	3.52e-04	193	32	3	627d345baf1940218c61907305705298e473dbab
ToppCell	3'-Broncho-tracheal-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NFKBIZ NR4A3 GRAP2	3.52e-04	193	32	3	349b6428f211c821844b11428d53de52be8a8f05
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature4_(1)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	NFKBIZ NR4A3 NUFIP2	3.52e-04	193	32	3	dbf0fe496254320c894568c31e5f9ce63707d1b5
ToppCell	distal-Hematologic-Basophil/Mast_2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NFKBIZ NR4A3 GRAP2	3.52e-04	193	32	3	dcdc1498726c68bf590bf84cb81e5f7fb7ba4d78
Drug	Strophantine octahydrate [11018-89-6]; Up 200; 5.4uM; HL60; HT_HG-U133A	ATXN2L NR4A3 TCF7L2 NFAT5 SEC24A	4.19e-06	174	32	5	1302_UP
Drug	(-)-depudecin; Down 200; 1uM; MCF7; HT_HG-U133A_EA	ZHX3 STAM2 TCF7L2 NFAT5 TNFRSF21	7.49e-06	196	32	5	874_DN
Drug	Amrinone [60719-84-8]; Down 200; 21.4uM; HL60; HT_HG-U133A	ATXN2L ARHGAP32 TCF7L2 FAM168A PDK4	7.87e-06	198	32	5	2724_DN
Drug	Sulfasalazine [599-79-1]; Up 200; 10uM; HL60; HG-U133A	NR4A3 TCF7L2 NFAT5 ATXN2 TNFRSF21	7.87e-06	198	32	5	1733_UP
Drug	Procaine hydrochloride [51-05-8]; Up 200; 14.6uM; MCF7; HT_HG-U133A	AUTS2 ATXN2L TCF7L2 TNFRSF21 PDK1	8.26e-06	200	32	5	1674_UP
Drug	VER-246608	PDK1 PDK4	1.91e-05	5	32	2	ctd:C000602510
Drug	Prenylamine lactate [69-43-2]; Up 200; 9.6uM; HL60; HG-U133A	TCF7L2 NFAT5 TNFRSF21 UTY	1.24e-04	184	32	4	1737_UP
Drug	Terbutaline hemisulfate [23031-32-5]; Up 200; 7.2uM; HL60; HG-U133A	ATXN2L NR4A3 TNFRSF21 UTY	1.27e-04	185	32	4	1585_UP
Drug	Corticosterone [50-22-6]; Up 200; 11.6uM; HL60; HT_HG-U133A	NR4A3 STAM2 FAM168A TNFRSF21	1.38e-04	189	32	4	1307_UP
Drug	Dicyclomine hydrochloride [67-92-5]; Up 200; 11.6uM; MCF7; HT_HG-U133A	AUTS2 NR4A3 NFAT5 TNFRSF21	1.41e-04	190	32	4	1483_UP
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	ATXN2L ZHX3 TCF7L2 NFAT5	1.44e-04	191	32	4	5567_DN
Drug	Pipenzolate bromide [125-51-9]; Up 200; 9.2uM; MCF7; HT_HG-U133A	ZHX3 LTBP2 TCF7L2 NFAT5	1.47e-04	192	32	4	3460_UP
Drug	Methiothepin maleate [19728-88-2]; Up 200; 8.4uM; HL60; HG-U133A	STAM2 TCF7L2 ATXN2 SEC24A	1.47e-04	192	32	4	1616_UP
Drug	Methylatropine nitrate [52-88-0]; Down 200; 11uM; HL60; HT_HG-U133A	ZHX3 NR4A3 ARHGAP32 TCF7L2	1.49e-04	193	32	4	3116_DN
Drug	Carbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A	ZHX3 TCF7L2 PDK4 SMAD4	1.52e-04	194	32	4	5342_UP
Drug	Mitoxantrone dihydrochloride [70476-82-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A	ZHX3 TCF7L2 UTY SMAD4	1.52e-04	194	32	4	5354_UP
Drug	Orphenadrine hydrochloride [341-69-5]; Up 200; 13uM; PC3; HT_HG-U133A	ZHX3 MAP3K13 PDK4 SEC24A	1.52e-04	194	32	4	4537_UP
Drug	Skimmianine [83-95-4]; Down 200; 15.4uM; MCF7; HT_HG-U133A	AUTS2 FAM168A NFAT5 PDK4	1.52e-04	194	32	4	6066_DN
Drug	Buspirone hydrochloride [33386-08-2]; Down 200; 9.4uM; MCF7; HT_HG-U133A	ZHX3 ARHGAP32 NFAT5 PDK1	1.52e-04	194	32	4	2637_DN
Drug	Sulfaphenazole [526-08-9]; Down 200; 12.8uM; HL60; HT_HG-U133A	STAM2 FAM168A NFAT5 PDK1	1.55e-04	195	32	4	1836_DN
Drug	17-AAG; Down 200; 1uM; SKMEL5; HG-U133A	ATXN2L ZHX3 NR4A3 ATXN2	1.55e-04	195	32	4	505_DN
Drug	Betahistine mesylate [54856-23-4]; Up 200; 17.2uM; MCF7; HT_HG-U133A	AUTS2 LTBP2 TCF7L2 PDK4	1.55e-04	195	32	4	2833_UP
Drug	Azapropazone [13539-59-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A	LTBP2 TCF7L2 TNFRSF21 SMAD4	1.55e-04	195	32	4	6522_DN
Drug	Homatropine hydrobromide (R,S) [51-56-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A	STAM2 TCF7L2 FAM168A TNFRSF21	1.59e-04	196	32	4	1684_UP
Drug	3-Acetamidocoumarin [779-30-6]; Down 200; 19.6uM; HL60; HT_HG-U133A	TCF7L2 NFAT5 ATXN2 UTY	1.59e-04	196	32	4	2941_DN
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; HL60; HT_HG-U133A	ATXN2L NR4A3 TCF7L2 TNFRSF21	1.59e-04	196	32	4	2936_DN
Drug	Folic acid [59-30-3]; Up 200; 9uM; MCF7; HT_HG-U133A	ATXN2L LTBP2 TCF7L2 TNFRSF21	1.59e-04	196	32	4	2783_UP
Drug	Muramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; HL60; HT_HG-U133A	NR4A3 STAM2 FAM168A SEC24A	1.59e-04	196	32	4	1326_UP
Drug	Ioversol [87771-40-2]; Down 200; 5uM; HL60; HT_HG-U133A	ATXN2L LTBP2 TCF7L2 SMAD4	1.62e-04	197	32	4	3026_DN
Drug	Terconazole [67915-31-5]; Down 200; 7.6uM; HL60; HT_HG-U133A	ATXN2L ARHGAP32 TCF7L2 UTY	1.62e-04	197	32	4	2484_DN
Drug	Cefmetazole sodium salt [56796-39-5]; Up 200; 8.2uM; HL60; HT_HG-U133A	ATXN2L LTBP2 TCF7L2 SEC24A	1.62e-04	197	32	4	2524_UP
Drug	troglitazone; Up 200; 10uM; MCF7; HT_HG-U133A	ATXN2L TCF7L2 UTY SMAD4	1.62e-04	197	32	4	6991_UP
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A	ATXN2L ZHX3 NFAT5 UTY	1.62e-04	197	32	4	1800_UP
Drug	CP-863187 [668981-07-5]; Down 200; 10uM; PC3; HT_HG-U133A	ATXN2L ARHGAP32 TCF7L2 PDK1	1.62e-04	197	32	4	7512_DN
Drug	Ampyrone [83-07-8]; Up 200; 19.6uM; MCF7; HT_HG-U133A	LTBP2 TNFRSF21 PDK4 SEC24A	1.62e-04	197	32	4	2249_UP
Drug	Condelphine [7633-69-4]; Down 200; 8.8uM; MCF7; HT_HG-U133A	ATXN2L ZHX3 STAM2 PDK1	1.62e-04	197	32	4	3538_DN
Drug	Oxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; HL60; HT_HG-U133A	STAM2 TCF7L2 ATXN2 TNFRSF21	1.62e-04	197	32	4	3006_DN
Drug	Colchicine [64-86-8]; Down 200; 10uM; MCF7; HT_HG-U133A	ZHX3 LTBP2 UTY PDK4	1.62e-04	197	32	4	5675_DN
Drug	Bemegride [64-65-3]; Down 200; 25.8uM; HL60; HT_HG-U133A	ATXN2L ZHX3 PRR14 LTBP2	1.65e-04	198	32	4	3051_DN
Drug	ST021200; Down 200; 10uM; MCF7; HT_HG-U133A	AUTS2 NFAT5 UTY SMAD4	1.65e-04	198	32	4	7554_DN
Drug	Cyproheptadine hydrochloride [969-33-5]; Up 200; 12.4uM; PC3; HG-U133A	STAM2 ARHGAP32 PRR14 NFAT5	1.65e-04	198	32	4	1938_UP
Drug	ionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA	ZHX3 ARHGAP32 TCF7L2 NFAT5	1.65e-04	198	32	4	871_DN
Drug	clozapine; Up 200; 10uM; HL60; HT_HG-U133A	NR4A3 STAM2 TCF7L2 NFAT5	1.65e-04	198	32	4	1170_UP
Drug	Dienestrol [84-17-3]; Down 200; 15uM; MCF7; HT_HG-U133A	STAM2 TCF7L2 FAM168A NFAT5	1.65e-04	198	32	4	6208_DN
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Up 200; 13.2uM; PC3; HG-U133A	ZHX3 PRR14 TCF7L2 PDK1	1.65e-04	198	32	4	1890_UP
Drug	Ketoprofen [22071-15-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	ATXN2L ZHX3 TCF7L2 PDK1	1.65e-04	198	32	4	2316_DN
Drug	Butamben [94-25-7]; Up 200; 20.6uM; HL60; HT_HG-U133A	ATXN2L LTBP2 TCF7L2 SMAD4	1.65e-04	198	32	4	2531_UP
Drug	rosiglitazone; Down 200; 10uM; HL60; HT_HG-U133A	ATXN2L ARHGAP32 TCF7L2 SEC24A	1.68e-04	199	32	4	2693_DN
Drug	Debrisoquin sulfate [581-88-4]; Up 200; 9uM; MCF7; HT_HG-U133A	ZHX3 LTBP2 TCF7L2 SMAD4	1.68e-04	199	32	4	3207_UP
Drug	Streptozotocin [18883-66-4]; Up 200; 15uM; HL60; HT_HG-U133A	STAM2 TCF7L2 TNFRSF21 SMAD4	1.68e-04	199	32	4	2535_UP
Drug	Paromomycin sulfate [1263-89-4]; Down 200; 5.6uM; HL60; HT_HG-U133A	STAM2 LTBP2 TCF7L2 PDK4	1.68e-04	199	32	4	3017_DN
Drug	Tetracaone hydrochloride [136-47-0]; Up 200; 13.2uM; HL60; HG-U133A	STAM2 TCF7L2 ATXN2 TNFRSF21	1.68e-04	199	32	4	1739_UP
Drug	Piroxicam [36322-90-4]; Up 200; 12uM; MCF7; HT_HG-U133A	ZHX3 TCF7L2 FAM168A PDK1	1.68e-04	199	32	4	7445_UP
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Down 200; 6.4uM; MCF7; HT_HG-U133A	STAM2 ARHGAP32 TCF7L2 NFAT5	1.68e-04	199	32	4	5283_DN
Drug	Cyclopenthiazide [742-20-1]; Down 200; 10.6uM; HL60; HT_HG-U133A	NR4A3 STAM2 ARHGAP32 UTY	1.71e-04	200	32	4	2905_DN
Drug	Super-Bond	ARHGAP32 GRAP2	3.22e-04	19	32	2	CID000123788
Drug	C2SI	ATXN2L ARHGAP32	3.58e-04	20	32	2	CID006327160
Disease	spinocerebellar ataxia type 2 (implicated_via_orthology)	ATXN2L ATXN2	1.07e-06	2	31	2	DOID:0050955 (implicated_via_orthology)
Disease	grip strength measurement	AUTS2 ATXN2L TCF7L2 TFAP2D NFAT5 SMAD4	1.53e-06	350	31	6	EFO_0006941
Disease	Drugs used in diabetes use measurement	AUTS2 LTBP2 TCF7L2 NFAT5 NUFIP2	6.55e-06	255	31	5	EFO_0009924
Disease	glucose measurement	AUTS2 ZHX3 TCF7L2 ATXN2 NUFIP2	4.45e-05	380	31	5	EFO_0004468
Disease	psoriasis, type 2 diabetes mellitus	NFKBIZ TCF7L2 ATXN2	6.74e-05	75	31	3	EFO_0000676, MONDO_0005148
Disease	autosomal dominant cerebellar ataxia (implicated_via_orthology)	ATXN2L ATXN2	7.00e-05	12	31	2	DOID:1441 (implicated_via_orthology)
Disease	cigarettes per day measurement	AUTS2 TCF7L2 NFAT5 SMAD4 NUFIP2	8.71e-05	438	31	5	EFO_0006525
Disease	body fat percentage	AUTS2 ATXN2L TCF7L2 TFAP2D NFAT5	1.44e-04	488	31	5	EFO_0007800
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	AUTS2 TCF7L2 FAM168A NFAT5 ATXN2 NUFIP2	1.62e-04	801	31	6	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	smoking status measurement	AUTS2 STAM2 TFAP2D FAM168A NFAT5 ATXN2 NUFIP2	1.64e-04	1160	31	7	EFO_0006527
Disease	Antihypertensive use measurement	AUTS2 TCF7L2 NFAT5 ATXN2	1.65e-04	265	31	4	EFO_0009927
Disease	waist-hip ratio	ZHX3 LTBP2 TCF7L2 TFAP2D FAM168A NFAT5 ATXN2	2.30e-04	1226	31	7	EFO_0004343
Disease	alcohol consumption measurement	AUTS2 ATXN2L ZHX3 TCF7L2 TFAP2D NFAT5 NUFIP2	2.49e-04	1242	31	7	EFO_0007878
Disease	clinical and behavioural ideal cardiovascular health	TCF7L2 NFAT5	2.67e-04	23	31	2	EFO_0007654
Disease	cerebellum cortex volume change measurement, age at assessment	TCF7L2 MAML2	3.42e-04	26	31	2	EFO_0008007, EFO_0021497
Disease	Polyarthritis, Juvenile, Rheumatoid Factor Positive	NR4A3 TCF7L2 MAML2	3.51e-04	131	31	3	C4704862
Disease	Polyarthritis, Juvenile, Rheumatoid Factor Negative	NR4A3 TCF7L2 MAML2	3.51e-04	131	31	3	C4552091
Disease	Juvenile arthritis	NR4A3 TCF7L2 MAML2	3.51e-04	131	31	3	C3495559
Disease	Juvenile psoriatic arthritis	NR4A3 TCF7L2 MAML2	3.51e-04	131	31	3	C3714758
Disease	Ischemic stroke	AUTS2 TCF7L2 ATXN2 TNFRSF21	3.55e-04	324	31	4	HP_0002140
Disease	Juvenile-Onset Still Disease	NR4A3 TCF7L2 MAML2	3.83e-04	135	31	3	C0087031
Disease	Amyotrophic Lateral Sclerosis With Dementia	ATXN2 TNFRSF21	4.26e-04	29	31	2	C0393554
Disease	longevity, healthspan, parental longevity	TCF7L2 ATXN2	4.26e-04	29	31	2	EFO_0004300, EFO_0007796, EFO_0009762
Disease	Amyotrophic Lateral Sclerosis, Guam Form	ATXN2 TNFRSF21	4.87e-04	31	31	2	C0543859
Disease	aspartate aminotransferase measurement, serum alanine aminotransferase measurement, low density lipoprotein triglyceride measurement, body fat percentage, high density lipoprotein cholesterol measurement, sex hormone-binding globulin measurement	AUTS2 ATXN2L TCF7L2 NFAT5	5.51e-04	364	31	4	EFO_0004612, EFO_0004696, EFO_0004735, EFO_0004736, EFO_0007800, EFO_0009946
Disease	alkaline phosphatase measurement	ZHX3 PRR14 LTBP2 NFAT5 ATXN2 NUFIP2	5.75e-04	1015	31	6	EFO_0004533
Disease	systolic blood pressure, body mass index	TCF7L2 ATXN2	5.87e-04	34	31	2	EFO_0004340, EFO_0006335
Disease	Abnormality of refraction	AUTS2 ZHX3 ARHGAP32 TCF7L2 FAM168A	6.32e-04	673	31	5	HP_0000539
Disease	dyslexia	AUTS2 IER5L POF1B	6.52e-04	162	31	3	EFO_0005424
Disease	Mitral valve prolapse	LTBP2 ATXN2	6.58e-04	36	31	2	HP_0001634
Disease	waist circumference	ATXN2L TCF7L2 TFAP2D NFAT5	1.02e-03	429	31	4	EFO_0004342
Disease	fibrinogen measurement, tissue plasminogen activator measurement	ATXN2L ATXN2	1.03e-03	45	31	2	EFO_0004623, EFO_0004791
Disease	fibrinogen measurement, plasminogen activator inhibitor 1 measurement	ATXN2L ATXN2	1.03e-03	45	31	2	EFO_0004623, EFO_0004792
Disease	pain	TCF7L2 ATXN2 NUFIP2	1.13e-03	196	31	3	EFO_0003843
Disease	severe acute respiratory syndrome, COVID-19	AUTS2 LTBP2 MAML2 GLI2	1.18e-03	447	31	4	EFO_0000694, MONDO_0100096
Disease	balding measurement	AUTS2 ZHX3 TCF7L2 MAML2 GLI2	1.31e-03	792	31	5	EFO_0007825
Disease	total cholesterol measurement, diastolic blood pressure, triglyceride measurement, systolic blood pressure, hematocrit, ventricular rate measurement, glucose measurement, body mass index, high density lipoprotein cholesterol measurement	ZHX3 TCF7L2	1.32e-03	51	31	2	EFO_0004340, EFO_0004348, EFO_0004468, EFO_0004530, EFO_0004574, EFO_0004612, EFO_0006335, EFO_0006336, EFO_0007928
Disease	peripheral arterial disease	TCF7L2 ATXN2	1.48e-03	54	31	2	EFO_0004265
Disease	Ischemic stroke, fibrinogen measurement	ATXN2L ATXN2	1.53e-03	55	31	2	EFO_0004623, HP_0002140
Disease	factor XI measurement, fibrinogen measurement, tissue plasminogen activator measurement, factor VII measurement	ATXN2L ATXN2	1.59e-03	56	31	2	EFO_0004619, EFO_0004623, EFO_0004694, EFO_0004791
Disease	Amyotrophic Lateral Sclerosis	ATXN2 TNFRSF21	1.70e-03	58	31	2	C0002736
Disease	biological sex	AUTS2 TCF7L2 ATXN2	1.79e-03	230	31	3	PATO_0000047
Disease	Sjogren syndrome	NFAT5 ATXN2	1.82e-03	60	31	2	EFO_0000699
Disease	alopecia	AUTS2 ZHX3 TCF7L2	2.04e-03	241	31	3	MONDO_0004907
Disease	type 1 diabetes mellitus	NR4A3 TCF7L2 ATXN2	2.07e-03	242	31	3	MONDO_0005147

Protein segments in the cluster

Peptide	Gene	Start	Entry
PVHFQQPQYLHQTHQ	CCNJ	271	Q5T5M9
YPHHATQLHAHQPQP	ATXN2L	861	Q8WWM7
QPAAVYAIHHQQLPH	ATXN2L	941	Q8WWM7
HHSQQYYQQIHHGEP	TFAP2D	96	Q7Z6R9
HHANRGVYPPIQVHV	PDK1	291	Q15118
DQPIHIVYVPSHLHH	PDK4	236	Q16654
HLPRYVQHLQRHPHS	PIP5KL1	166	Q5T9C9
PQNQHVEQQPHYTHK	NFKBIZ	291	Q9BYH8
PVYAAQPHVIHHTTV	FAM168A	156	Q92567
LVQHVPHYQSQHPHV	ATXN2	1051	Q99700
QHTHQHTFTPFPHAI	AUTS2	536	Q8WXX7
HPVQSYPQQSHHLAA	GLI2	1316	P10070
SVPPHHNKLEQHQVY	ARHGAP32	1506	A7KAX9
QNHLIVKVPPYHDQH	NFAT5	501	O94916
AQCHHHIIQQPQVIH	POF1B	186	Q8WVV4
QHVPHEHYNQPHEDI	CBLL1	246	Q75N03
AHHHPEYQGQPVVSH	CBLL1	316	Q75N03
PPPDYHHHHQQHLLN	MAML2	126	Q8IZL2
LHQAQSQYPSLHHHN	MAP3K13	621	O43283
VHIHHPPEASVQIHQ	LTBP2	476	Q14767
QPPQQRYLQHHHFHQ	GRAP2	216	O75791
QPPHHQHQHLAYAAP	IER5L	66	Q5T953
HLQQQLHQHQHPAPR	IER5L	121	Q5T953
HHHQQQHQQPSIPPA	NR4A3	106	Q92570
FHQFPQHPVHVSVVH	SND1-IT1	81	Q9HBX3
VPYLQQNTHTLPHNH	UTY	556	O14607
QVVNHQQGPHHRHIL	TNFRSF21	296	O75509
YPSYHHQHNPVQVQK	SEC24A	716	O95486
PQHHSYHQDPVHRQP	PRR14	76	Q9BWN1
YTPNLPHHQNGHLQH	SMAD4	276	Q13485
HHHPHHHPQQQQQQP	NUFIP2	16	Q7Z417
NKVPVVQHPHHVHPL	TCF7L2	186	Q9NQB0
HRNPPLHYEHQVVQS	MYCBPAP	596	Q8TBZ2
TVPAHPVAQQHTNYH	STAM2	506	O75886
PSPAAHYHQLHVHLQ	nan	56	Q6Q795
QQPPVHAQHHVHQPL	ZHX3	276	Q9H4I2